Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | GALR3 | O60755 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.47 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519586 | 0.90 | HPGD (0.56) | RAB9ANPC1HPGDGALR3ATM | |
| SCHEMBL4534518 | 0.88 | HPGD (0.62) | RAB9ANPC1HPGDKMT2APOLB | |
| SCHEMBL4523937 | 0.87 | HPGD (0.64) | RAB9ANPC1HPGDKMT2APOLB | |
| SCHEMBL4520705 | 0.84 | HPGD (0.62) | RAB9ANPC1HPGDVNN1ALDH1A1 | |
| SCHEMBL4522870 | 0.82 | HPGD (0.67) | RAB9ANPC1HPGDKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL4560091 | 0.81 | HPGD (0.66) | RAB9ANPC1HPGDKMT2AALDH1A1 | |
| SCHEMBL4520206 | 0.81 | HPGD (0.58) | RAB9ANPC1HPGDKMT2APOLB | |
| SCHEMBL4521372 | 0.81 | HPGD (0.68) | RAB9ANPC1HPGDVNN1ALDH1A1 | |
| SCHEMBL4530457 | 0.78 | HPGD (0.67) | RAB9ANPC1HPGDVNN1ALDH1A1 | |
| SCHEMBL4527873 | 0.77 | HPGD (0.97) | HPGDPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286797-A1 | Novel Quinoxaline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-19 | — | — | US | claimed |
| EP-1960373-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-08-27 | — | — | EP | claimed |
| WO-2007060144-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-05-31 | — | — | WO | claimed |
| US-20090286797-A1 | Novel Quinoxaline Derivatives and Their Medical Use | NEUROSEARCH A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| EP-1960373-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007060144-A2 | NOVEL QUINOXALINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286797-A1 | Novel Quinoxaline Derivatives and Their Medical Use | GRM2, GRIK5, GRIN2A | RAB9A 1184/4885NPC1 2530/4885HPGD 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.